natgillin/translations-raw huggingface dataset:
ADROVANCE studies
Ispitivanja lijeka ADROVANCE
ADRs (INTELENCE + BR versus Placebo + BR)
Nuspojave (INTELENCE + BR naspram placebo + BR)
ADRs are listed in Table 3 below by MedDRA system organ class and by frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to
Nuspojave su navedene u Tablici 3 prema MedDRA-klasifikaciji organskih sustava i učestalosti: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do
ADRs considered by the investigator to be possibly, probably, or remotely related to the administration of capecitabine are listed in Table 4 for capecitabine given as monotherapy and in Table 5 for capecitabine given in combination with different chemotherapy regimens in multiple indications.
Nuspojave na lijek koje je naveo ispitivač kao moguće, vjerojatno ili slabo povezane s primjenom kapecitabina navedene su u Tablici 4 za kapecitabin u monoterapiji i u Tablici 5 za kapecitabin u različitim kemoterapijskim protokolima pri različitim indikacijama.
ADRs from clinical studies (Table 1) are listed by MedDRA system organ class.
Nuspojave lijeka iz kliničkih ispitivanja (Tablica 1) navedene su prema MedDRA klasifikaciji organskih sustava.
ADRs from psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies (Table 1) are listed by MedDRA system organ class.
Nuspojave iz kliničkih ispitivanja psorijaze, psorijatičnog artritisa i ankilozantnog spondilitisa (Tablica 1) navedene su prema MedDRA-inoj klasifikaciji organskih sustava.
ADRs observed in clinical studies and reported from world-wide post-marketing use of golimumab are listed in Table 1.
Nuspojave zabilježene u kliničkim ispitivanjima i prijavljene širom svijeta nakon stavljanja golimumaba u promet navedene su u Tablici 1.
ADRs of moderate intensity or greater (≥ grade 2) reported in patients treated with INTELENCE are summarised in table 2 (background regimen is indicated as “BR”).
Umjerene ili ADR većeg intenziteta (≥ 2. stupnja) koje su prijavljene kod bolesnika liječenih INTELENCEom sažete su u tablici 2 (osnovno liječenje označeno je kao “BR”-background regimen).
ADRs related to afatinib.
nuspojava povezanih s afatinibom.
ADRs reported are on treatment or up to 28 days post treatment end date.
Prijavljene nuspojave na lijek pojavile su se tijekom liječenja ili do 28 dana nakon zadnjeg dana liječenja.
ADRs reported from the use of Velphoro at doses from 250 mg iron/day to 3,000 mg iron/day in these patients (n=835) are listed in Table 1.
Nuspojave na lijek prijavljene pri primjeni lijeka Velphoro u dozama od 250 mg željeza/dan do 3000 mg željeza/dan u tih bolesnika (n=835) prikazane su u Tablici 1.
ADRs reported in ≥ 1 % of necitumumab treated patients in SQUIRE
Nuspojave lijeka prijavljene u ≥ 1 % bolesnika liječenih necitumumabom u ispitivanju SQUIRE
ADRs specific to residues from the manufacturing process
Nuspojave na lijek specifične za ostatne tvari iz proizvodnog postupka
ADRs which were reported are listed below by MedDRA body system organ class and by frequency.
Prijavljene nuspojave na lijek u nastavku su navedene prema MedDRA klasifikaciji organskih sustava i učestalosti.
ADRs with an incidence of ≥10% were diarrhoea, nausea, vomiting, fatigue, liver laboratory test abnormalities, abdominal pain, decreased appetite, constipation, rash, blood creatinine increased, oesophageal disorder and anaemia.
Nuspojave s incidencijom ≥10% bile su proljev, mučnina, povraćanje, umor, abnormalnosti na laboratorijskim pretragama jetre, bol u abdomenu, smanjeni apetit, konstipacija, osip, povišeni kreatinin u krvi, poremećaj jednjaka i anemija.
adsorbed on amorphous aluminium hydroxyphosphate sulphate (0.5 mg Al).
adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0,5 mg Al)
Adsorbent: strips (2.5 x 20 cm) for thin layer chromatography coated with silica gel (ITLC-SG) or for paper chromatography (RBM-1).
Adsorbent: trake (2,5 x 20 cm) za tankoslojnu kromatografiju prevučene silikagelom (ITLC- SG) ili za kromatografiju na papiru (RBM-1).
Adsorption and distribution
Apsorpcija i distribucija
Adult (73.7 kg)
Odras la osoba (73,7 kg)
Adult (>18 years)
Odrasli (>18 godina)
Adult and adolescents (13 to 17 years of age) Reconstitution
Odrasli i adolescenti (u dobi od 13 do 17 godina) Rekonstitucija
Adult and older adults (≥65 years) population
Odrasli i populacija starijih odraslih osoba (≥65 godina)
Adult and paediatric
Odrasli i pedijatrijski bolesnici
Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).
Odrasli i pedijatrijski bolesnici (1 do 17 godina starosti) s kompliciranim infekcijama kože i mekih tkiva.
Adult and paediatric haemodialysis patients, adult peritoneal dialysis patients and adult patients with renal insufficiency not yet undergoing dialysis
Odrasli i pedijatrijski bolesnici na hemodijalizi, odrasli bolesnici na peritonejskoj dijalizi i odrasli bolesnici s renalnom insuficijencijom koji još nisu na dijalizi
Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma
Odrasli bolesnici i pedijatrijski bolesnici u dobi od 3 godine ili stariji s recidivirajućim ili progresivnim malignim gliomom:
Adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
Odraslih i pedijatrijskih bolesnika s novodijagnosticiranom kroničnom mijeloičnom leukemijom (KML) s pozitivnim Philadelphia (Ph+) kromosomom (bcr-abl), u kojih se transplantacija koštane srži ne smatra prvom linijom liječenja.
Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
Odraslih i pedijatrijskih bolesnika s novodijagnosticiranom akutnom limfoblastičnom leukemijom s pozitivnim Philadelphia kromosomom (Ph+ ALL) uz kemoterapiju.
Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
Odraslih i pedijatrijskih bolesnika s Ph+ KML-om u kroničnoj fazi nakon neuspjeha terapije interferonom-alfa, ili u ubrzanoj fazi ili u blastičnoj krizi.
Adult cancer patients with symptomatic anaemia receiving chemotherapy
Odrasli bolesnici s malignim bolestima sa simptomatskom anemijom koji primaju kemoterapiju
Adult Child
Odrasla osoba Dijete
Adult chronic hepatitis C prior treatment non-responder patients
Kronični hepatitis C u odraslih bolesnika koji nisu odgovorili na ranije liječenje
Adult Crohn’s disease
Crohnova bolest u odraslih
Adult Crohn’s disease
Crohnova bolest u odraslih bolesnika
Adult Crohn’s disease Flixabi is indicated for: treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
Crohnova bolest u odraslih bolesnika Flixabi je indiciran za: liječenje umjerenog do teškog oblika aktivne Crohnove bolesti u odraslih bolesnika koji nisu odgovorili na punu i odgovarajuću terapiju nekim kortikosteroidom i/ili imunosupresivom, odnosno u onih koji ne podnose ili imaju medicinske kontraindikacije za takve terapije liječenje fistulirajuće, aktivne Crohnove bolesti u odraslih bolesnika koji nisu odgovorili na punu i odgovarajuću konvencionalnu terapiju (uključujući antibiotike, drenažu i imunosupresijsku terapiju).
Adult Crohn’s disease Inflectra is indicated for: treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
Crohnova bolest u odraslih bolesnika Inflectra je indicirana za: liječenje umjerenog do teškog oblika aktivne Crohnove bolesti u odraslih bolesnika koji nisu odgovorili na punu i odgovarajuću terapiju nekim kortikosteroidom i/ili imunosupresivom, odnosno u onih koji ne podnose ili imaju medicinske kontraindikacije za takve terapije. liječenje fistulirajuće, aktivne Crohnove bolesti u odraslih bolesnika koji nisu odgovorili na punu i odgovarajuću konvencionalnu terapiju (uključujući antibiotike, drenažu i imunosupresijsku terapiju).
Adult Crohn’s disease Remicade is indicated for: treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
Crohnova bolest u odraslih bolesnika Remicade je indiciran za: liječenje umjerenog do teškog oblika aktivne Crohnove bolesti u odraslih bolesnika koji nisu odgovorili na punu i odgovarajuću terapiju nekim kortikosteroidom i/ili imunosupresivom, odnosno u onih koji ne podnose ili imaju medicinske kontraindikacije za takve terapije. liječenje fistulirajuće, aktivne Crohnove bolesti u odraslih bolesnika koji nisu odgovorili na punu i odgovarajuću konvencionalnu terapiju (uključujući antibiotike, drenažu i imunosupresijsku terapiju).
Adult Crohn’s disease Remsima is indicated for: treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
Crohnova bolest u odraslih bolesnika Remsima je indicirana za: liječenje umjerenog do teškog oblika aktivne Crohnove bolesti u odraslih bolesnika koji nisu odgovorili na punu i odgovarajuću terapiju nekim kortikosteroidom i/ili imunosupresivom, odnosno u onih koji ne podnose ili imaju medicinske kontraindikacije za takve terapije. liječenje fistulirajuće, aktivne Crohnove bolesti u odraslih bolesnika koji nisu odgovorili na punu i odgovarajuću konvencionalnu terapiju (uključujući antibiotike, drenažu i imunosupresijsku terapiju).
Adult female
Odrasla žena
adult female
odrasle žene
Adult female 57 kg
Odrasla žena 57 kg
Adult male
Odrasli muškarac
adult male
odrasli muškarci
adult male (70 kg)
odrasli muškarac (70 kg)
Adult male 70 kg
Odrasli muškarac 70 kg
Adult male and female subjects were enrolled in two pharmacokinetic studies.
Odrasli ispitanici oba spola bili su uključeni u dva farmakokinetička istraživanja.
Adult onset: Patients who have severe growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and who have at least one known deficiency of a pituitary hormone not being prolactin.
Nastup u odrasloj dobi: Bolesnici s teškom deficijencijom hormona rasta povezanom s deficijencijom drugih hormona zbog poznate hipotalamičke ili hipofizne patologije i nedostatkom najmanje jednog hormona hipofize koji nije prolaktin.
Adult patients (16 years of age and above) should use Protopic 0.1% ointment.
Odrasli bolesnici (u dobi od 16 ili više godina) trebaju primjenjivati Protopic 0,1% mast.
Adult Patients (18 years of age or older): Ribavirin Mylan is indicated in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum HCV-RNA (see section 4.4).
Odrasli bolesnici (starosti 18 godina ili više): Ribavirin Mylan je, u kombinaciji s interferonom alfa- 2b, indiciran za liječenje odraslih bolesnika sa svim vrstama kroničnog hepatitisa C osim genotipa 1, koji prethodno nisu bili liječeni, nemaju dekompenziranu funkciju jetre, imaju povišene vrijednosti alanin aminotransferaze (ALT) i pozitivan nalaz ribonukleinske kiseline virusa hepatitisa C (HCV- RNK) u serumu (vidjeti dio 4.4).
Adult patients on haemodialysis
Odrasli bolesnici na hemodijalizi
Adult patients on peritoneal dialysis
Odrasli bolesnici na peritonejskoj dijalizi
Adult patients should use Protopic 0.1% ointment.
Odrasli bolesnici trebaju primjenjivati Protopic 0,1% mast.
Adult patients suffering from acute coronary syndrome:
odraslih bolesnika koji boluju od akutnog koronarnog sindroma:
Adult patients suffering from acute coronary syndrome:
Odraslih bolesnika s akutnim koronarnim sindromom:
Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
35 dana), ishemijski moždani udar (u rasponu od 7 dana do najviše 6 mjeseci) ili imaju utvrđenu bolest perifernih arterija.
Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
odraslih bolesnika koji su pretrpjeli infarkt miokarda (u rasponu od nekoliko do najviše 35 dana), ishemijski moždani udar (u rasponu od 7 dana do najviše 6 mjeseci) ili imaju utvrđenu bolest perifernih arterija.
Adult patients who have previously taken other antiviral medicines can take Kaletra tablets once daily as an 800 mg/200 mg dose if their doctor decides it is appropriate.
Odrasli bolesnici koji su prethodno uzimali druge antivirusne lijekove mogu uzimati Kaletra tablete jednom dnevno u dozi od 800 mg/200 mg ako je njihov liječnik tako odlučio.
Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Odraslih bolesnika s uznapredovalim hipereozinofilnim sindromom (HES) i/ili kroničnom eozinofilnom leukemijom (KEL) s preuredbom FIP1L1-PDGFR.
Adult patients with hyperphosphataemia (serum phosphorus levels ≥1.94 mmol/L) were treated with Velphoro at a starting dose of 1,000 mg iron/day followed by an 8-week dose titration period.
Odrasli bolesnici s hiperfosfatemijom (razine fosfora u serumu ≥1,94 mmol/l) liječeni su lijekom Velphoro uz početnu dozu od 1000 mg željeza/dan nakon čega je uslijedilo 8­tjedno razdoblje titracije doze.
Adult patients with moderate renal impairment (creatinine clearance of 30-50 mL/minute) should be administered alternating daily doses of 200 mg and 400 mg.
Odrasli bolesnici s umjerenim oštećenjem bubrega (klirens kreatinina 30 – 50 ml/min) trebaju primijeniti naizmjenične dnevne doze od 200 mg i 400 mg.
Adult patients with moderate renal impairment (creatinine clearance of 30-50 mL/minute) should be administered alternating daily doses of 200 mg and 400 mg.
U odraslih bolesnika s umjerenim oštećenjem funkcije bubrega (klirens kreatinina 30–50 ml/min) treba naizmjence primjenjivati dnevne doze od 200 mg i 400 mg.
Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
Odraslih bolesnika s mijelodisplastičnim/mijeloproliferativnim bolestima (MDS/MPB) povezanim s preuredbom gena za receptor faktora rasta koji potječe od trombocita (PDGFR).
Adult patients with newly - diagnosed glioblastoma multiforme
Odrasli bolesnici s novodijagnosticiranim multiformnim glioblastomom
Adult patients with newly-diagnosed glioblastoma multiforme
Bolesnici s novodijagnosticiranim multiformnim glioblastomom:
Adult patients with newly-diagnosed glioblastoma multiforme:
Odrasli bolesnici s novodijagnosticiranim multiformnim glioblastomom
Adult patients with newly-diagnosed glioblastoma multiforme:
Stariji bolesnici s novodijagnosticiranim multiformnim glioblastomom
Adult patients with non-radiographic axial spondyloarthritis
Odrasli bolesnici s aksijalnim spondiloartritisom bez radiografskog dokaza
Adult patients with RA
Odrasli bolesnici s RA
Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
Odraslih bolesnika s recidivirajućom ili refraktornom Ph+ ALL kao monoterapija.
Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
Odraslih bolesnika s recidivirajućom ili refraktorrnom Ph+ ALL kao monoterapija.
Adult patients with renal insufficiency not yet undergoing dialysis
Odrasli bolesnici s renalnom insuficijencijom koji još nisu na dijalizi
Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.
Odrasli bolesnici s desnostranim infektivnim endokarditisom izazvanim sa Staphylococcus aureus.
Adult patients with Staphylococcus aureus bacteraemia (SAB) when associated with RIE or with cSSTI.
Odrasli bolesnici sa Staphylococcus aureus bakterijemijom kada je udružena s desnostranim infektivnim endokarditisom ili s kompliciranom infekcijom kože i mekih tkiva.
Adult patients: Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed. (see section 5.1).
Odrasli bolesnici: Ribavirin Teva indiciran je, u kombinaciji s interferonom alfa-2b, za liječenje odraslih bolesnika s kroničnim hepatitisom C koji su odgovorili na prethodno liječenje (uz normalizaciju vrijednosti ALT na kraju liječenja) interferonom alfa primijenjenim u monoterapiji, ali u kojih je kasnije došlo do relapsa (vidjeti dio 5.1).
Adult patients: Ribavirin Teva Pharma B.V. is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1 , not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA (see section 4.4).
Odrasli bolesnici: Ribavirin Teva Pharma B.V. indiciran je, u kombinaciji s interferonom alfa- 2b, za liječenje odraslih bolesnika sa svim vrstama kroničnog hepatitisa C, osim genotipa 1, koji prethodno nisu liječeni, koji nemaju dekompenzaciju jetre, koji imaju povišenu razinu alanin aminotransferaze (ALT) i koji su pozitivni na ribonukleinsku kiselinu HCV-RNK hepatitis C virusa (vidjeti dio 4.4).
Adult patients: Ribavirin Teva Pharma B.V. is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.(see section 5.1).
Odrasli bolesnici: Ribavirin Teva Pharma B.V. indiciran je, u kombinaciji s interferonom alfa- 2b, za liječenje odraslih bolesnika s kroničnim hepatitisom C koji su odgovorili na prethodno liječenje (uz normalizaciju vrijednosti ALT na kraju liječenja) interferonom alfa primijenjenim u monoterapiji, ali u kojih je kasnije došlo do relapsa (vidjeti dio 5.1).
Adult population (including elderly)
Odrasli bolesnici (uključujući starije osobe)
Adult surgery patients in an autologous predonation programme
Odrasli bolesnici pred operaciju u autolognom predonacijskom programu
Adult surgery patients in an autologous predonation programme.
Odrasli bolesnici pred operaciju u autolognom predonacijskom programu
Adult type 1 and type 2 diabetes titration guideline:
Smjernice za titraciju u odraslih bolesnika koji imaju šećernu bolest tipa 1 i 2:
Adult type 2 diabetes simple self titration guideline:
Smjernice za samotitraciju u odraslih bolesnika koji imaju šećernu bolest tipa 2:
Adult women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth,
Odraslih žena podvrgnutih superovulaciji prije tehnika potpomognute oplodnje, kao što je in vitro (IVF): Ovitrelle se daje za pokretanje konačnog sazrijevanja folikula i luteinizaciju nakon stimulacije rasta folikula,
Adult women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth,
Odraslih žena podvrgnutih superovulaciji prije tehnika potpomognute oplodnje, kao što je in vitro oplodnja (IVF): Ovitrelle se daje za pokretanje konačnog sazrijevanja folikula i luteinizaciju nakon stimulacije rasta folikula,
Adult-Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis are severe autoinflammatory diseases, driven by innate immunity by means of pro-inflammatory cytokines, a key one being IL-1- beta.
Stillova bolest odrasle dobi i sistemski juvenilni idiopatski artritis teške su autoinflamatorne bolesti, koje potiče prirođeni imunitet pomoću proinflamatornih citokina, od kojih je ključni IL-1-beta.
Adult: ≥ 12g/dL (females); ≥ 13g/dL (males)
Odrasli: ≥ 12 g/dl (žene); ≥ 13 g/dl (muškarci)
Adults
Odrasla osoba
adults
odraslih
Adults (1,500 mg/m2) N=103 (%)
Odrasli (1,500 mg/m2) N=103 (%)
Adults (18 years and older):
Odrasli (s 18 godina i više)
Adults (18 years and older): 2 inhalations twice a day.
Odrasli (s 18 godina i više) 2 inhalacije dvaput dnevno.
Adults (18 years and older): 2 inhalations twice daily
Odrasli (s 18 godina i stariji): 2 inhalacije dvaput dnevno
Adults (18 years and older): 2 inhalations twice daily.
Odrasli (s 18 godina i stariji): 2 inhalacije dvaput dnevno.
Adults (18 years or above)
Odrasli (18 godina ili stariji)
Adults (18-60 years)
Odrasli (18 do 60 godina)
Adults (18-65 years of age)
Odrasli (18 do 65 godina)
Adults (aged 18-65 years), adolescents (aged 12-17 years), infants and children (aged from nine months to 11 years)
Odrasli (u dobi od 18 do 65 godina), adolescenti (u dobi od 12 do 17 godina), dojenčad i djeca (u dobi od devet mjeseci do 11 godina)
Adults (from 18 to 60 years old) and elderly (over 60 years old):
Odrasle (u dobi od 18 do 60 godina) i starije osobe (od 60 godina naviše):
Adults (including elderly patients)
Odrasli (uključujući starije bolesnike)
Adults (over 18 years of age)
Odrasle osobe (u dobi iznad 18 godina)
Adults (≥18 years old)
odrasli (u dobi ≥ 18 godina)
Adults (≥18 years)
Odrasli (≥18 godina)
Adults - Duration of treatment - HCV/HIV co-infection
Odrasli – trajanje liječenja - istodobna infekcija HCV-om i HIV-om
Adults - Duration of treatment – Naïve patients Tritherapy: Refer to the SmPC for boceprevir.
Odrasli – trajanje liječenja – bolesnici koji prethodno nisu bili liječeni Trojna terapija: Pročitajte Sažetak opisa svojstava lijeka za boceprevir.
Adults - the usual starting dose for SAA is one 50 mg tablet of Revolade a day.
Odrasli – uobičajena početna doza za tešku aplastičnu anemiju je jedna tableta lijeka Revolade od 50 mg na dan.
Adults - the usual starting dose for SAA is two 25 mg sachets of Revolade a day.
Odrasli – uobičajena početna doza za tešku aplastičnu anemiju su dvije vrećice lijeka Revolade od 25 mg na dan.
Adults 18 years of age and older
Odrasli u dobi od 18 godina i stariji
Adults >21 years
Odrasli u dobi ˃21 godine
Adults >30 years
Odrasli >30 godina
Adults aged 18 to 49 had an immune response with Prevenar 13 which was as good as the response in adults aged 60 to 64.
Odrasle osobe u dobi od 18 do 49 godina imale su imunološki odgovor s lijekom Prevenar 13, koji je bio podjednako dobar kao odgovor u odraslih osoba u dobi od 60 do 64 godine.